TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ESSA Pharma ( (EPIX) ) has issued an announcement.
On August 25, 2025, ESSA Pharma Inc. clarified a previous announcement regarding the trading of its common shares with ‘due bills’ for a capital distribution. The correct trading period with due bills was from August 19 to August 22, 2025, after which shares traded on an ‘ex-dividend’ basis. This announcement is part of the company’s winding-up process following a transaction with XenoTherapeutics, Inc., where Xeno will acquire all outstanding shares.
The most recent analyst rating on (EPIX) stock is a Hold with a $2.25 price target. To see the full list of analyst forecasts on ESSA Pharma stock, see the EPIX Stock Forecast page.
Spark’s Take on EPIX Stock
According to Spark, TipRanks’ AI Analyst, EPIX is a Neutral.
ESSA Pharma’s overall score reflects significant financial challenges with no revenue and ongoing losses. Technical indicators provide some positive signals, but caution is advised due to potential overbought conditions. The negative P/E ratio and lack of dividends further underline investment risks.
To see Spark’s full report on EPIX stock, click here.
More about ESSA Pharma
ESSA Pharma Inc. is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.
Average Trading Volume: 325,088
Technical Sentiment Signal: Sell
Current Market Cap: $91.31M
See more data about EPIX stock on TipRanks’ Stock Analysis page.